National Academies Press: OpenBook

Monoclonal Antibody Production (1999)

Chapter: References

« Previous: Conclusions and Recommendations
Suggested Citation:"References." National Research Council. 1999. Monoclonal Antibody Production. Washington, DC: The National Academies Press. doi: 10.17226/9450.
×

References

Akerstrom, B., T. Brodin, K. Reis, L. Bjorck. 1985. Protein G: A powerful tool for binding and detection of monoclonal and polyclonal antibodies. J Immunol 135:2589–2592.

Amyx, H.L. 1987. Control of animal pain and distress in antibody production and infectious disease studies. J Am Vet Med Assoc 191:1287–1289.

Anon. 1989. Code of Practice for the Production of Monoclonal Antibodies. Vet Health Inspectorate 6 pp. Rijswijk, The Netherlands.

Ausubel, F.M., R. Brent, R.E. Kingston, D.D. Moore. J.G. Seidman, J.A. Smith, K. Struhl, eds. 1998. Current protocols in molecular biology. V.B. Chanada, series ed. New York: Wiley & Sons.


Barclay, R.J., W.J. Herbert, T.B. Poole. 1988. The disturbance index: A behavioural method of assessing the severity of common laboratory procedures on rodents, 36 pp. Potters Bar, Herts., UK: UFAW.

Beck, C., H. Stiefel, T. Stinnett. 1987. Cell-culture bioreactors. Chem. Eng. Feb 16, 1987:121–129.

Boraston, R., P. Thompson, S. Garland, J. Birch. 1984. Growth and oxygen requirements of antibody producing mouse hybridoma. Cells in suspension culture. Develop Biol Standard 55:103–111.

Boyd, J.E., K. James. 1989. Human monoclonal antibodies: Their potential, problems, and prospects. Pp. 1–43 in Monoclonal Antibodies: Production and Application. A. Mizrahi, ed. New York: Alan R. Liss, Inc.

Brodeur, B., P. Tsang, 1986. High yield monoclonal antibody production in ascites. J Immunol Methods 86:239–241.

Brodeur, B.R., P. Tsang, Y. Larose. 1984. Parameters affecting ascites tumor formation in mice and monoclonal antibody production. J Immunol Methods 71:265–272.

Burnside, JW., T.J. McGlynn. 1987. P. 226 in Physical Diagnosis. Baltimore: Williams & Wilkins.

Butler, M., N. Huzel. 1995. The effect of fatty acids on hybridoma cell growth and antibody productivity in serum-free cultures. J Biotech 39:165–173.


CAAT (Center for Alternatives to Animal Testing) and OPRR (Office for Protection from Research Risks). 1997. Alternatives in Monoclonal Antibody Production Workshop. Baltimore, MD: Johns Hopkins.

CAAT (Center for Alternatives to Animal Testing). 1997. Technical Report #8 Alternatives in Monoclonal Antibody Production. Baltimore, MD:Johns Hopkins.

Suggested Citation:"References." National Research Council. 1999. Monoclonal Antibody Production. Washington, DC: The National Academies Press. doi: 10.17226/9450.
×

Cancro, M., M. Potter. 1976. The requirement of an adherent cell substratum for the growth of developing plasmacytoma cell in vivo. J Exp Med 144:1554–1567.

Capiaumont, J., C. Legrand, D. Carbonell, B. Dousset, F. Belleville, P. Nabet. 1995. Methods for reducing the ammonia in hybridoma cell cultures. J Biotech 39:49–58.

Chandler, J. 1987. Factors influencing monoclonal antibody production in mouse ascites fluid. Pp. 75–92 in Commercial Production of Monoclonal Antibodies. S. Seaver, ed. New York:Marcel Dekker, Inc.

Chandler, J. 1998. In Testimony Before the National Research Council's Committee on Monoclonal Antibody Production. November 10, 1998: Washington, DC.

Chua, F.K.F., M.G.S. Yap, S.K.W. Oh. 1994a. Hyper-stimulation of monoclonal antibody production by high osmolarity stress in eRDF medium. J Biotech 37:265–275.

Chua, F.K.F., S.K.W. Oh, M Yap, W.K. Teo. 1994b. Enhanced IgG production in eRDF media with and without serum. J Immunol Methods 167:109–119.

Coligan, J.E., A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W. Strober, eds. 1998. Current protocols in immunology. R. Coico, series ed. New York: Wiley & Sons.

Darby, C., K. Hamano, K. Wood. 1993. Purification of monoclonal antibodies from tissue culture medium depleted of IgG. J Immunol 159: 125–129.

deGeus, B., C. Hendriksen, eds. 1998a. 74th Forum in Immunology: In vivo and in vitro production of monoclonal antibodies: Current possibilities and future perspectives. Res Immunol 149:529–620.

de Geus, B., C. Hendriksen. 1998b. In vivo and in vitro production of monoclonal antibodies—Introduction. Res Immunol 149:533–534.

Detolla, L.J. 1998. In Testimony Before the National Research Council's Committee on Monoclonal Antibody Production. November 10, 1998: Washington, DC


Evans, T., R. Miller. 1988. Large-scale production of murine monoclonal antibodies using hollow fiber bioreactors. BioTechniques 6:762–767.


FDA (Food and Drug Administration, Center for Biologics Evaluation and Research). 1997. Points to consider in the manufacture and testing of monoclonal antibody products for human use. Washington, DC: FDA.

Falkenberg, F., H. Weichert, M. Krane. 1995. In vitro production of monoclonal antibodies in high concentration in a new and easy to handle modular minifermentor. J Immunol 179:13–29.

Federspiel, G., K.C. McCullough, U. Kihm. 1991. Hybridoma antibody production in vitro in type II serum-free medium using Nutridoma-SP supplements. Comparison with in vivo methods. J Immunol 145:213–221.

Frenken, L.G.J., J.G.M. Hessing, C.A. Van den Hondel, C.T. Verrips. 1998. Recent advances in the large-scale production of antibody fragments using lower eukaryotic microorganisms. Res Immunol 149(6):589–599.


Gillette, R.W. 1987. Alternatives to pristane priming for ascitic fluid and monoclonal antibody production. J Immunol Methods 99:21–23.


Halder, H., M. Embelton, R. Fischer, B. de Geus, C. Hendriksen, W. de Leeuw, U. Marx, M. Balls. 1998. Comments on Appendix C of the National Institutes of Health response to the petition of the American Anti-Vivisection Society to prohibit the use of animals in the production of monoclonal antibodies. ATLA 26:549–554.

Harlow, E., D. Lane. 1988. Antibodies: A laboratory manual. New York: Cold Spring Harbor Laboratory Press.

Heidel, J. 1997. Monoclonal antibody production in gas-permeable tissue culture bags using serum-free media. Center for Alternatives to Animal Testing: Alternatives in Monoclonal Antibody Production 8:18–20.

Hendriksen, C., J. Rozing, M. VanderKamp, W. deLeeuw. 1996. The production of monoclonal antibodies: Are animals still needed? ATLA 24:109–110.

Suggested Citation:"References." National Research Council. 1999. Monoclonal Antibody Production. Washington, DC: The National Academies Press. doi: 10.17226/9450.
×

Hendriksen, C., W. de Leeuw. 1998. Production of monoclonal antibodies by the ascites method in laboratory animals. Res Immunol 149:535–542.

Hoffmann, P., M. Jiménez-Diaz, J. Weckesser, W.G. Bessler. 1996. Murine bone marrow-derived macrophages constitute feeder cells for human B cell hybridomas. J Immunol Methods 196:85–91.

Hoogenraad, N.J., C.J. Wraight. 1986. The effect of pristane on ascites tumor formation and monoclonal antibody production. Methods Enzymol 121:3715–385.

IRAC (Interagency Research Animal Committee). 1983. U.S. Government Principles for the Utilization and Care of Vertebrate Animals Used in Testing, Research and Training. (See OPRR, 1996)

Ishaque, A., M. Al-Rubeai. 1998. Use of intracellular pH and annexin-V flow cytometric assays to monitor apoptosis and its suppression by bcl-2 over-expression in hybridoma cell culture. J Immunol Methods 221:43–57.


Jackson, L.R., J.G. Fox. 1995. Institutional policies and guidelines on adjuvants and antibody production. ILAR J 37:141–151

Jackson, L., L. Trudel, J. Fox, N. Lipman. 1996. Evaluation of hollow fiber bioreactors; as an alternative to murine ascites production for small scale monoclonal antibody production. J Immunol Methods 189:217–231.

Jackson, L.R., L.J. Trudel, J.G. Fox, N.S. Lipman. 1999a. Monoclonal antibody production in murine ascites: I. Clinical and pathological features. Lab Anim Sci 49:70–80.

Jackson, L.R., L.J. Trudel, J.G. Fox, N.S. Lipman. 1999b. Monoclonal antibody production in murine ascites: II. Production features. Lab Anim Sci 49:81–86.

Jaspert, R., T. Geske, A. Teichmann, Y.M Kabner, K. Kretzschman, J. L'age-Stehr. 1995. Laboratory scale production of monoclonal antibodies in a tumbling chamber. J Immunol Methods 178:77–87.


Klerx, J., C. Jansen Verplanke, C. Blonk, L. Twaalfhoven. 1988. In vitro production of monoclonal antibodies under serum-free conditions using a compact and inexpensive hollow fibre cell culture unit. J Immunol Methods I 11:179–188.

Knazek, R., P. Gullino, P. Kohler, R. Dedrick. 1972. Cell culture on artificial capillaries. Science 178:65–67.

Köhler, G., C. Milstein. 1975. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495–497.

Kurkela, R., E. Fraune, P. Vihko. 1993. Pilot-scale production of murine monoclonal antibodies in agitated, ceramic-matrix, or hollow-fiber cell culture systems. BioTechniques 15:674–693.


Lebherz, W. 1987. Batch production of monoclonal antibody by large-scale suspension culture. Pp. 93–118 in Commercial Production of Monoclonal Antibodies. S. Seaver, ed. New York:Marcel Dekker.

Leibiger, H., A. Hansen, G. Schoenherr, M. Seifert, D. Wóstner, R Stigler, U. Marx. 1995. Glycosylation analysis of a polyreactive human monoclonal IgG antibody derived from a human-mouse heterohybridoma. Mol Immunol 32(8):595–602.

Linscott's Directory of Immunological Biological Reagents. 10th Edition. 1998–1999. Santa Rosa, CA.

Lipman, N. 1997. Hollow fibre bioreactors: An alternative to the use of mice for monoclonal antibody production. Pp. 10–15. in Alternatives in Monoclonal Antibody Production. Johns Hopkins Center for Alternatives to Animal Testing Technical Report #8.

Loeb, W., F. Quimby. (eds.). 1999. The Clinical Chemistry of Laboratory Animals, 2nd Edition. Philadelphia, PA:Taylor and Francis.

Lullau, E., Heyse, S., Vogel, H., Marlson, I., VonStockar, U., Kraehenbuhl, JP, Corthesy, B. 1996. Antigen binding properties of purified immunoglobulin A and reconstituted secretory immunoglobulin A antibodies. J Biol Chem 271:16300–16309.

Suggested Citation:"References." National Research Council. 1999. Monoclonal Antibody Production. Washington, DC: The National Academies Press. doi: 10.17226/9450.
×

Maiorella B.L., J. Winkelhake, J. Young, B. Moyer, R. Bauer, M. Hora, J. Andya, J. Thomson, T. Patel, R. Parekh. 1993. Effect of culture conditions on IgM antibody structure, pharmacokinetics, and activity. Biotechnology 11:387–392.

Marx, U. 1998. Membrane-based cell culture technologies: A scientifically and economically satisfactory alternative to malignant ascites production for monoclonal antibodies. Res Immunol 149:557–559.

Marx, U., M.J. Embleton, R. Fischer, F.P. Gruber, U.Hansson, J. Heuer, W.A. de Leeuw, T. Logtenberg, W. Merz, D. Portetelle, J.L. Romette, D.W. Straughan. 1997. Monoclonal antibody production: The report and recommendations of ECVAM Workshop 23. ATLA 25:121–137.

Matsuuchi, L., L.A. Wims, S.L. Morrison. 1981. A variant of the dextran-binding mouse plasmacytoma J558 with altered glycosylation of its heavy chain and decreased reactivity with polymeric dextran. Biochemistry 20:4827–4835.

Mauch, P.M., J.E. Ultmann. 1985. Treatment of malignant ascites. Pp. 2150–2153 in Cancer: Principles and Practice of Oncology. vol. 2, 2nd ed., V.T. DeVita, S. Hellman, and S.A. Rosenberg, eds. Philadelphia: Lippincott.

Maxim, P. 1998. In Testimony Before the National Research Council's Committee on Monoclonal Antibody Production. November 10, 1998; Washington, D.C.

McGuill, M.W., A.N. Rowan. 1989. Refinement of monoclonal antibody production and animal well-being. ILAR News 31:7–11.

Miller, W., C. Wilke, H. Blanch. 1987. Effects of dissolved oxygen concentration on hybridoma growth and metabolism in continuous culture. J Cell Physiol 132:524–30.

Monica, T.J., C.F. Goochee, B.L. Maiorella. 1993. Comparative biochemical characterization of a human IgM produced in both ascites and in vitro cell culture. Biotechnology 11:512–515.

Moro, A.M., M.T. Rodrigues, M.N. Gouvea, M.L. Silvestri, J.E. Kalil, I. Raw. 1994. Multiparametric analyses of hybridoma growth on glass cylinders in a packed-bed bioreactor system with internal aeration. Serum-supplemented and serum-free media comparison for mAb production. J Immunol Methods Nov. 10; 176(1):67–77.


Ness, T.J., G.F. Gebhart. 1990. Visceral pain: A review of experimental studies. Pain 41:167–234.

Ness, T.J., G.F. Gebhart. 1988. Colorectal distension as a noxious visceral stimulus: Physiologic and pharmacologic characterization of pseudoaffective reflexes in the rat. Brain Res 450:153–169.

NIH (National Institutes of Health). 1996. Public Health Service Policy on Humane Care and Use of Laboratory Animals. Bethesda, MD: Office for Protection from Research Risks.

NIH (National Institutes of Health). 1997. Production of Monoclonal Antibodies Using Mouse Ascites Method. 98–01. Rockville, MD: Office for Protection from Research Risks, Nov. 17, 1997.

NRC (National Research Council). 1996. Guide for the Care and Use of Laboratory Animals. A report of the Institute for Laboratory Animal Research Committee to Revise the Guide. Washington, D.C.: National Academy Press.

NRC (National Research Council). 1992. Recognition and Alleviation of Pain and Distress. A report of the Institute for Laboratory Animal Research Committee on Pain and Distress in Laboratory Animals. Washington. D.C.: National Academy Press.


Ohlin, M., C.A. Borrebaeck. 1994. Flow cytometric analysis of the stability of antibody production by human × human × mouse heterohybridoma subclones. J Immunol Methods Mar. 29; 170(1):75–82.


Patel, S.S., R.B. Parekh, B.J. Moellering, C.P. Prior. 1992. Different culture methods lead to differences in glycosylation of a murine IgG monoclonal antibody. J Biochem 285:839–845.

Peterson, N., J. Peavey 1998. Comparison of in vitro monoclonal antibody production methods with an in vivo ascites production technique. Contemp Top Lab Anim Sci 37(5):61–66.

Pockros, P.J., T.B. Reynolds. 1986. Rapid diuresis in patients with ascites from chronic liver disease: The importance of peripheral edema. Gastroenterology 90:1827–1833.

Suggested Citation:"References." National Research Council. 1999. Monoclonal Antibody Production. Washington, DC: The National Academies Press. doi: 10.17226/9450.
×

Poncet, P., T. Matthcs, A. Billecocq, G. Dighiero. 1988. Immunochemical studies of polyspecific natural autoantibodies: Charge, lipid reactivity, Fab 2' fragment activity and complement fixation. M Immunol 25:981–989.

Quinlan, N., R. O'Kennedy. 1994. Enhanced cloning effeciencies of murine hybridomas using human plasma supplemented medium. J Immunol Methods 171:253–258.


Reuveny, S., A. Lazar. 1989. Equipment and procedures for production of monoclonal antibodies in culture. Adv Biotechnol Processes 11:45–80.

Reuveny, S., D. Velez, J. Macmillan, L. Miller. 1985. Factors affecting monoclonal antibody production in culture. Develop Biol Std 66:169–175.

Reuveny, S., Velez, S., J. Macmillan, L. Miller. 1986. Factors affecting cell growth and monoclonal antibody production in stirred reactors. J Immunol Methods 86:53–59.

Richards, H.B., M. Satoh, M. Shaw, C. Libert, V. Poli, W.H. Reeves. 1998. Interleukin 6 dependence of anti-DNA antibody production: Evidence for two pathways of autoantibody formation in pristane-induced lupus. J Exp Med 188:985–990.

Roggenbuck, D., U. Marx, S.T. Kiessig, O. Schoenherr, S. Lahn T., Porstmann. 1994. Purification and immunochemical characterization of a natural human polyreactive monoclonal IgM antibody. J Immunol Methods 167:207–218,


Satoh, M., W.H. Reeves. 1994. Induction of lupus-associated autoantibodies in BALB/c mice by intraperitoneal injection of pristane. J Exp Med 180:2341–2346.

Seaver, S. 1987. Culture method affects antibody secretion of hybridoma. cells. Pp. 49–71 in Commercial Production of Monoclonal Antibodies. S. Seaver, Ed. New York:Marcel Dekker, Inc.

Shacter, E. 1989. Serum-free media for bulk culture of hybridoma cells and the preparation of monoclonal antibodies. Trends Biotechnol 7:248–253.

Stang, B.V., P.A. Wood, J.J. Reddington, G.M. Reddington, J.R. Heidel. 1998, Monoclonal antibody production in gas-permeable flexible flasks, using serum-free media. Contemp Top Lab Anim Sci 37(6):55–60.

Stein, K. 1998. In Testimony Before the National Research Council's Committee on Monoclonal Antibody Production. November 10, 1998; Washington, D.C.

Stoll, T.S., C. Perregaux, U. von Stockar, I.W. Marison. 1995. Production of Immunoglobulin A in different reactor configurations. Cytotechnology 17:53–63.

Stoll T.S., P.A. Ruffieux, E. Lullau, U. von Stockar, I.W. Marison. 1996a. Characterization of monoclonal IgA production and activity in hollow-fiber and fluidized-bed reactors. Pp. 608–614 in Immobilized Cells: Basics and Applications, R.H. Wijffels, R.M. Buitolarr, C. Bucke, J. Tramper, eds. The Netherlands: Elsevier Science B.V.

Stoll, T.S., K. Muhlethaler, U. von Stockar, I.W. Marison. 1996b. Systematic improvement of a chemically-defined protein-free medium for hybridoma growth and monoclonal antibody production. J Biotechnol. Feb. 28;45(2):111–123.

Stoll, T., A. Chappaz, U. von Stockar, I.W. Marison. 1997. Effects of culture conditions on the production and quality of monoclonal IgA. Enzyme Mitrob Technol 21:203–211.


Tarleton, R., A. Beyer. 1991. Medium-scale production and purification of monoclonal antibodies in protein-free medium. BioTechniques 11:590–593.

Trampler, F., S.A. Sonderhoff, P.W.S. Pui, D.G. Kilburn, J.M. Piret. 1994. Acoustic cell filter for high density perfusion culture of hybridoma cells. Bio/Technol 12:281–284.


Underwood, P.A., P.A. Bean. 1985. The influence of methods of production, purification and storage of monoclonal antibodies upon their observed specificities. J Immunol Methods 80:189–197.

UKCCR. 1998. United Kingdom Co-ordinating Committee on Cancer Research. Guidelines for the Welfare of Animals in Experimental Neoplasia (Second Edition). 1998. Br J Cancer 77(1):1–10.


Vachula, M., F. Aono, M. Alzona, K. Kowalkowski, D. Van Epps. 1995. Growth and phenotype of a pheresis product mononuclear cells cultured in life cell flasks in serum-free media with combinations of IL-2, OKT3, and anti-CD28. Exp Hematol 23:661.

Suggested Citation:"References." National Research Council. 1999. Monoclonal Antibody Production. Washington, DC: The National Academies Press. doi: 10.17226/9450.
×

Varmus, H. 1997. Response to the petition requesting the National Institutes of Health to prohibit the use of animals and implement non-animal alternatives in the production and use of monoclonal antibodies. Appendix C. Sept. 18, 1997; Bethesda, MD.

Velez, D., S. Reuveny, L. Miller, J. Macmillan. 1986. Kinetics of monoclonal antibody production in low serum medium. J Immunol Methods 86:45–52.

Ware, C., N. Donato, K. Dorshkind. 1985. Human, rat or mouse hybridomas secrete high levels of monoclonal antibodies following transplantation into mice with severe combined immunodeficiency disease (SCID). J Immunol Methods 85:353–361.

Wolf, M. 1998. CL6-well experimental screening device application: Murine and rat hybridoma. CELLine Technical Report IV.

Wright, A., S.L. Morrison. 1994. Effect of altered CH2-associated carbohydrate structure on the functional properties and in vivo fate of chimeric mouse-human immunoglobulin GI. J Exp Med 180:1087–1096.

Wright, A, S.L. Morrison. 1998. Effect of C2-associated structure on Ig effector function: Studies with chimeric mouse-human IgGI antibodies in glycosylation mutants of Chinese hamster ovary cells. J Immunol 160:3393–3402.

Wright, A, S.L. Morrison. 1997. Effect of glycosylation on antibody function: Implications for genetic engineering. Trends Biotechnol 15:26–32.

Suggested Citation:"References." National Research Council. 1999. Monoclonal Antibody Production. Washington, DC: The National Academies Press. doi: 10.17226/9450.
×
This page in the original is blank.
Suggested Citation:"References." National Research Council. 1999. Monoclonal Antibody Production. Washington, DC: The National Academies Press. doi: 10.17226/9450.
×
Page 48
Suggested Citation:"References." National Research Council. 1999. Monoclonal Antibody Production. Washington, DC: The National Academies Press. doi: 10.17226/9450.
×
Page 49
Suggested Citation:"References." National Research Council. 1999. Monoclonal Antibody Production. Washington, DC: The National Academies Press. doi: 10.17226/9450.
×
Page 50
Suggested Citation:"References." National Research Council. 1999. Monoclonal Antibody Production. Washington, DC: The National Academies Press. doi: 10.17226/9450.
×
Page 51
Suggested Citation:"References." National Research Council. 1999. Monoclonal Antibody Production. Washington, DC: The National Academies Press. doi: 10.17226/9450.
×
Page 52
Suggested Citation:"References." National Research Council. 1999. Monoclonal Antibody Production. Washington, DC: The National Academies Press. doi: 10.17226/9450.
×
Page 53
Suggested Citation:"References." National Research Council. 1999. Monoclonal Antibody Production. Washington, DC: The National Academies Press. doi: 10.17226/9450.
×
Page 54
Next: Appendix A: Workshop on Methods of Producing Monoclonal Antibodies »
Monoclonal Antibody Production Get This Book
×
Buy Paperback | $47.00 Buy Ebook | $37.99
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

The American Anti-Vivisection Society (AAVS) petitioned the National Institutes of Health (NIH) on April 23, 1997, to prohibit the use of animals in the production of mAb. On September 18, 1997, NIH declined to prohibit the use of mice in mAb production, stating that "the ascites method of mAb production is scientifically appropriate for some research projects and cannot be replaced." On March 26, 1998, AAVS submitted a second petition, stating that "NIH failed to provide valid scientific reasons for not supporting a proposed ban." The office of the NIH director asked the National Research Council to conduct a study of methods of producing mAb.

In response to that request, the Research Council appointed the Committee on Methods of Producing Monoclonal Antibodies, to act on behalf of the Institute for Laboratory Animal Research of the Commission on Life Sciences, to conduct the study. The 11 expert members of the committee had extensive experience in biomedical research, laboratory animal medicine, animal welfare, pain research, and patient advocacy (Appendix B). The committee was asked to determine whether there was a scientific necessity for the mouse ascites method; if so, whether the method caused pain or distress; and, if so, what could be done to minimize the pain or distress. The committee was also asked to comment on available in vitro methods; to suggest what acceptable scientific rationale, if any, there was for using the mouse ascites method; and to identify regulatory requirements for the continued use of the mouse ascites method.

The committee held an open data-gathering meeting during which its members summarized data bearing on those questions. A 1-day workshop (Appendix A) was attended by 34 participants, 14 of whom made formal presentations. A second meeting was held to finalize the report. The present report was written on the basis of information in the literature and information presented at the meeting and the workshop.

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    Switch between the Original Pages, where you can read the report as it appeared in print, and Text Pages for the web version, where you can highlight and search the text.

    « Back Next »
  6. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  7. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  8. ×

    View our suggested citation for this chapter.

    « Back Next »
  9. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!